Skip to content

All courses

Industry track, The AI Decision Course

AI in life sciences and pharma

For leaders in life sciences and pharma: where AI pays first, how far it should go into clinical trials, validating it like any other GxP system, what it may run in the plant, and when safety work escalates to a person.

10 lessons, about 4 hours with the exercises, 10 cards your team fills in.

Part of The AI Decision Course: membership is annual and includes all 21 courses, with a full refund within 14 days.

About this course

This course covers bringing AI into life sciences and pharma: where it pays first and where it must wait, closing the loop between the model and the lab, and what AI really shortens in drug research. It also covers how far AI goes into clinical trials, the submission that stops at the draft, GxP validation, what AI may run in the GMP plant, which safety work it takes, what it may write for doctors and patients, and the lab that runs itself.

You leave able to pick the first workflow where documents pile up and someone already verifies every output, to validate the workflow around the model rather than the model alone, and to keep the release decision on the batch with your quality unit. You can also let AI draft the submission and stop at the draft, with a named human tier clearing every piece that reaches doctors or patients.

Lessons in this course

  1. Where AI pays first in life sciences, and where it must wait5-minute read, Free to readEnds in First AI workflow card, 20-minute exercise
  2. Close the loop between the model and the lab4-minute readEnds in Lab loop readiness card, 20-minute exercise
  3. What AI really shortens in drug research2-minute readEnds in Drug research AI claim card, 20-minute exercise
  4. How far AI should go into your clinical trials3-minute readEnds in Trial AI rung card, 20-minute exercise
  5. Let AI draft the submission, and stop at the draft3-minute readEnds in Submission verification card, 20-minute exercise
  6. Validate the AI like any other GxP system3-minute readEnds in AI GxP validation card, 20-minute exercise
  7. What AI may run in the GMP plant, and who signs the batch4-minute readEnds in Plant AI boundary card, 20-minute exercise
  8. Which safety work AI takes, and what escalates to a person3-minute readEnds in Drug safety AI split card, 20-minute exercise
  9. What AI may draft for doctors and patients3-minute readEnds in AI content tiers card, 20-minute exercise
  10. When the lab runs itself, keep the scientist in the loop4-minute readEnds in Lab-readiness card, 20-minute exercise

What you leave with

One card per lesson, blank and with a worked example, so the decision is written down before the meeting where it is made.

  • First AI workflow card
  • Lab loop readiness card
  • Drug research AI claim card
  • Trial AI rung card
  • Submission verification card
  • AI GxP validation card
  • Plant AI boundary card
  • Drug safety AI split card
  • AI content tiers card
  • Lab-readiness card

Back to the course list

Questions

Where should we start with AI in pharma?

Start where the documents pile up, in a workflow with high document volume and a human already verifying every output. If an output enters a submission, batch record, safety file or trial record, it waits for the GxP gate, and a GxP-ready claim is believed only after your reviewers grade the output on your own documents. The lesson 'Where AI pays first in life sciences, and where it must wait' covers the pick.

How do we validate AI in a GxP environment?

Let quality rule on whether the output touches a regulated record, and write the intended use down: a research assistant needs light checks, while a use feeding a regulated record gets validation sized to its risk. A new model version or drift outside its boundaries reopens part of the validation, and the signature stays human. The lesson 'Validate the AI like any other GxP system' covers it.

Can AI decide anything in the GMP plant?

Let the model watch the process and draft the investigation, suggesting a draft severity and categorization that the investigator settles. The release decision on the batch stays with your quality unit, and the trail shows the inspector what the model touched, how it was validated and who decided. The lesson 'What AI may run in the GMP plant, and who signs the batch' covers the line.

The other courses in the membership